Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Common Equity (2020 - 2026)

Cytek Biosciences filings provide 6 years of Common Equity readings, the most recent being $341.7 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 13.64% to $341.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $341.7 million, a 13.64% decrease, with the full-year FY2025 number at $341.7 million, down 13.64% from a year prior.
  • Common Equity hit $341.7 million in Q4 2025 for Cytek Biosciences, down from $378.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $425.5 million in Q4 2022 to a low of -$11.0 million in Q2 2021.
  • Median Common Equity over the past 5 years was $394.4 million (2023), compared with a mean of $357.8 million.
  • Biggest five-year swings in Common Equity: soared 36940.18% in 2022 and later fell 13.64% in 2025.
  • Cytek Biosciences' Common Equity stood at $405.4 million in 2021, then grew by 4.97% to $425.5 million in 2022, then dropped by 7.63% to $393.1 million in 2023, then rose by 0.68% to $395.7 million in 2024, then fell by 13.64% to $341.7 million in 2025.
  • The last three reported values for Common Equity were $341.7 million (Q4 2025), $378.6 million (Q3 2025), and $377.6 million (Q2 2025) per Business Quant data.